BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
May 04, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AVE1642: Development discontinued

sanofi-aventis discontinued development of AVE1642 due to a reprioritization of its R&D portfolio and returned rights to ImmunoGen. AVE1642 was in Phase II...

Read the full 92 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >